Results Healthcare has advised Sanofi on the divestment of its Holmes Chapel manufacturing site to

  • Service: Divestments
  • Sector: Healthcare
  • Sub Sector: CROs & CMOs, Pharma & Biotech
  • Engagement Type: Sell Side
Jun 2018
has divested its Holmes Chapel manufacturing site to

The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market. It also adds additional inhalation commercial drug product manufacturing capabilities, complementing services already offered by Recipharm’s inhalation development facility in the US.

Thomas Eldered, CEO of Recipharm, commented: “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilising our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility”.

Sector Related Deals

Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Feb 2021
has been acquired by
Jan 2021
has invested in
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to
Jan 2021
has divested its Ringaskiddy analytics and testing site to
Oct 2020
has been acquired by
a Gilde Healthcare-backed company